CTIS2023-509572-42-00招募中1 期
A Phase 1b/2 Open-Label, Multicenter Study of RMC-6236 in Combination with Pembrolizumab with or without Chemotherapy, in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol B - RMC-LUNG-101B
Revolution Medicines Inc.0 个研究点目标入组 405 人开始时间: 2024年3月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 405
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Patients that are at least 18 years old. Patients that have NSCLC with certain RAS mutations. Patients that have NSCLC that is unlikely to be cured and has spread to other body parts. Patients that have received prior cancer treatment. Patients that have at least one tumor lesion (an area of abnormal tissue) that can be measured. Patients that have adequate organ function (bone marrow, liver, kidney).
排除标准
- •1. Participants that have primary brain and spinal cord tumor spreading to other body parts. 2. Participants that have gastrointestinal problems that may affect absorption of RMC-6236. 3. Participants that had any major surgery in the last 4 weeks. 4. Participants that have have previously taken targeted therapy for RAS mutation. 5. Participants that have any other medical condition that may interfere with the study drugs.
研究者
相似试验
招募中
1 期
A study of RMC-6291 in combination with pembrolizumab in participants with solid tumors with certain mutations- Subprotocol Aung CancerMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-509571-16-00Revolution Medicines Inc.345
进行中（未招募）
1 期
A clinical study of the compound MCS110 in combination with the compound PDR001 in patients with advanced cancersEUCTR2016-000210-29-DEovartis Pharma Services AG175
进行中（未招募）
1 期
A clinical study of the compound MCS110 in combination with the compound PDR001 in patients with advanced cancersEUCTR2016-000210-29-FRovartis Pharma Services AG175
进行中（未招募）
1 期
A clinical study of the compound MCS110 in combination with the compound PDR001 in patients with advanced cancersadvanced malignanciesMedDRA version: 18.1Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2016-000210-29-ESovartis Farmacéutica, S.A.141
进行中（未招募）
1 期
A clinical study of the compound MCS110 in combination with the compound PDR001 in patients with advanced cancersadvanced malignanciesMedDRA version: 21.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2016-000210-29-FIovartis Pharma Services AG175